1,090 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by PUREfi Wealth LLC

PUREfi Wealth LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,090 shares of the medical research company’s stock, valued at approximately $214,000.

A number of other large investors also recently bought and sold shares of the business. Creative Planning grew its holdings in IQVIA by 17.8% in the third quarter. Creative Planning now owns 21,013 shares of the medical research company’s stock worth $4,980,000 after purchasing an additional 3,176 shares during the last quarter. Good Life Advisors LLC purchased a new position in IQVIA in the third quarter worth $443,000. Global Retirement Partners LLC increased its holdings in shares of IQVIA by 1.3% during the third quarter. Global Retirement Partners LLC now owns 10,686 shares of the medical research company’s stock valued at $2,532,000 after acquiring an additional 138 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of IQVIA by 4.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 48,826 shares of the medical research company’s stock valued at $11,570,000 after purchasing an additional 1,931 shares during the last quarter. Finally, V Square Quantitative Management LLC raised its position in shares of IQVIA by 4.1% in the 3rd quarter. V Square Quantitative Management LLC now owns 4,260 shares of the medical research company’s stock valued at $1,009,000 after purchasing an additional 168 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 1.2 %

Shares of IQV opened at $193.65 on Friday. The firm has a market cap of $35.15 billion, a P/E ratio of 25.82, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The company’s 50-day moving average price is $200.41 and its 200 day moving average price is $218.21. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the subject of several research analyst reports. The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Robert W. Baird decreased their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Morgan Stanley increased their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Finally, William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $251.67.

Insiders Place Their Bets

In related news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the transaction, the director now owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.